Canaprin 5000iu (Heparin Sodium)

Product Overview

Canaprin 5000iu is a sterile, pharmaceutical-grade solution of Heparin Sodium, specifically formulated for intravenous administration in patients at risk of acute myocardial infarction. Each vial contains 5000 international units of heparin sodium dissolved in 5 ml of sterile water for injection, providing a standardized anticoagulant effect suitable for acute coronary syndrome management. The product is manufactured by Healing Pharma, an Indian pharmaceutical company that adheres to WHO‑GMP standards, ensuring consistency, purity, and batch‑to‑batch reproducibility. Packaged in an amber glass vial with a rubber stopper and aluminum seal, Canaprin 5000iu is supplied in cartons of 6, 12, or 3 vials, allowing clinicians to select the most appropriate pack size for hospital formularies or private practice.

What is Canaprin 5000iu

Canaprin 5000iu refers to the specific dosage strength of heparin sodium that delivers 5000†IU per vial. Heparin is a naturally occurring glycosaminoglycan that potentiates the activity of antithrombin III, thereby accelerating the inhibition of thrombin and factor Xa. This mechanism reduces the formation of fibrin clots within the coronary vasculature, making the medication a cornerstone in the prevention of thrombotic complications during acute coronary events. The term “Canaprin” is a proprietary brand name used by Healing Pharma to denote this particular formulation, which is distinguished by its sterile preparation, precise dosing, and compliance with international pharmacopeial specifications. For a detailed scientific overview, see the Wikipedia entry on heparin.

Uses and Benefits

Clinicians prescribe Canaprin 5000iu primarily for the prophylaxis of postoperative venous thromboembolism and for the treatment of acute myocardial infarction when combined with other antiplatelet agents. In the acute setting, early administration of heparin has been shown to reduce the incidence of recurrent ischemic events, improve myocardial perfusion, and lower the need for repeat revascularization procedures. Additional benefits include compatibility with a wide range of cardiac monitoring devices, minimal impact on renal function at therapeutic doses, and a well‑characterized safety profile that supports use in diverse patient populations, including the elderly, provided dosing is adjusted for weight and renal clearance. More information on clinical outcomes can be found at the National Institutes of Health (NIH).

How It Works

The pharmacodynamics of Canaprin 5000iu hinge on its ability to bind to antithrombin, a serine protease inhibitor, and induce a conformational change that greatly enhances its capacity to inactivate thrombin (factor IIa) and factor Xa, the latter being a pivotal enzyme in the coagulation cascade. By selectively dampening the intrinsic and extrinsic pathways, heparin reduces the generation of fibrin, the insoluble protein that forms the mesh of a clot. This anticoagulant effect is dose‑dependent; the 5000†IU dose provides a therapeutic window that balances clot prevention with the risk of excessive bleeding, especially when monitored with activated partial thromboplastin time (aPTT) assays. Detailed mechanistic studies are summarized by the U.S. Food and Drug Administration (FDA).

Dosage Guidelines

The recommended adult dosage of Canaprin 5000iu for acute coronary syndrome is typically 70†IU/kg administered intravenously as a bolus, followed by a continuous infusion of 18†IU/kg per hour, adjusted according to serial aPTT measurements targeting 1.5–2.5 times the control value. For patients undergoing percutaneous coronary intervention, a weight‑based bolus may be followed by a lower infusion rate to maintain the desired anticoagulant effect while minimizing bleeding complications. Pediatric dosing, patients with severe renal impairment, and those with a history of heparin‑induced thrombocytopenia require individualized dosing and close laboratory monitoring. Always consult the prescribing information and perform baseline renal function tests before initiating therapy. Refer to the MedlinePlus drug entry for additional guidance.

Side Effects

Like all anticoagulants, Canaprin 5000iu can produce adverse effects, the most common being minor bleeding at the injection site, bruising, or prolonged clotting time. More serious but less frequent complications include major hemorrhage, heparin‑induced thrombocytopenia (HIT), and allergic reactions characterized by rash or pruritus. Rarely, patients may experience acute kidney injury, especially when high cumulative doses are administered in conjunction with contrast agents. Patients should be advised to report any signs of unusual bleeding, sudden drop in platelet count, or unexplained abdominal pain immediately to their healthcare provider. Further safety data are available on Drugs.com.

Warnings and Precautions

Canaprin 5000iu is contraindicated in individuals with known hypersensitivity to heparin or any component of the formulation, as well as in patients with active bleeding disorders or recent hemorrhagic stroke. Caution is advised in those with severe hepatic disease, uncontrolled hypertension, or recent major surgery, as these conditions increase the risk of uncontrolled bleeding. Prior to administration, obtain a thorough medical history, assess current medications for potential drug interactions (e.g., aspirin, clopidogrel, direct oral anticoagulants), and perform baseline laboratory tests including platelet count and renal function. Pregnant or lactating women should only receive the medication when the anticipated benefit justifies the potential risk, and dosing should be closely supervised. Additional regulatory information can be accessed via the FDA website.

Frequently Asked Questions

Q: What is the storage condition for Canaprin 5000iu?
A: Store at 2‑8†°C in a refrigerator, protected from light. Do not freeze.

Q: Can Canaprin be used in patients with diabetes?
A: Yes, but monitor blood glucose closely as heparin can affect metabolic parameters; consult your physician.

Q: How long does the anticoagulant effect last after a dose?
A: The anticoagulant effect begins within minutes and can persist for 6–12†hours, depending on dose and individual metabolism.

Q: Is it safe to use Canaprin alongside aspirin?
A: Combining heparin with aspirin is common in acute coronary care, but the combination increases bleeding risk; medical supervision is required.

Q: Where can I find the full prescribing information?
A: The complete product monograph is available on the manufacturer’s website and can be accessed through authoritative drug databases such as Drugs.com or the FDA’s label repository (see link).